<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687046</url>
  </required_header>
  <id_info>
    <org_study_id>1868-705-008</org_study_id>
    <nct_id>NCT04687046</nct_id>
  </id_info>
  <brief_title>A Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adults Using Real-World Evidence</brief_title>
  <official_title>A Real-World Evidence Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect effectiveness and safety data on JUVÉDERM VOLUX® Injectable Gel for&#xD;
      Chin Enhancement in Chinese Adults based on real world data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 30 participants selected who undergo 3D imaging before and after JUVÉDERM&#xD;
      VOLUX® treatment for digital analysis assessments. Up to 90 participants enrolled either&#xD;
      prospectively prior to JUVÉDERM VOLUX® treatment or retrospectively after JUVÉDERM VOLUX®&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Glabella-Subnasale-Pogonion (G-Sn-Pog) Angle</measure>
    <time_frame>Baseline, Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders based on the Investigator's Assessment of Improvement in the Chin and Jaw Area using the 5-point Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Month 3</time_frame>
    <description>The Evaluating Investigator will assess the aesthetic improvement of the hands using the GAIS 5- point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders based on the Participant's Assessment of Improvement in the Chin and Jaw Area using the 5-point GAIS</measure>
    <time_frame>Month 3</time_frame>
    <description>Participant will assess the aesthetic improvement of the hands using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence and severity of ISRs (Injection Site Response) at scheduled follow-up visits</measure>
    <time_frame>Month 1, 3, 6, and 12</time_frame>
    <description>The number of patients who experienced ISRs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of Adverse Events (AEs) from physician observation and inquiry at scheduled follow-up visits</measure>
    <time_frame>Month 1, 3, 6, and 12</time_frame>
    <description>The number of patients who experienced AEs</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chin Retrusion</condition>
  <arm_group>
    <arm_group_label>Cohort 1 JUVÉDERM VOLUX® with 3D Imaging</arm_group_label>
    <description>Treatment will be determined according to the physician's experience and Directions for Use. Cohort 1 will have follow-up on-site visits, including 3D imaging, at Months 1, 3, 6, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 JUVÉDERM VOLUX®</arm_group_label>
    <description>Treatment will be determined according to the physician's experience and Directions for Use. Cohort 2 will have follow-up on-site visits at Months 1 and 3 and follow-up telephone calls at Months 6 and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM VOLUX®</intervention_name>
    <description>JUVÉDERM VOLUX® injectable gel</description>
    <arm_group_label>Cohort 1 JUVÉDERM VOLUX® with 3D Imaging</arm_group_label>
    <arm_group_label>Cohort 2 JUVÉDERM VOLUX®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All participants receive VOLUX treatment at Hainan Boao Super Hospital, with screening and&#xD;
        follow-up visits at Hainan Boao Super Hospital or another hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has chin retrusion seeking chin enhancement who have received or plan to&#xD;
             receive VOLUX chin treatment in Hainan Boao Super Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to lidocaine,HA, or Streptococcal protein&#xD;
&#xD;
          -  History of tendency to develop hypertrophic scarring&#xD;
&#xD;
          -  Untreated epilepsy or porphyria&#xD;
&#xD;
          -  Current cutaneous inflammatory or infectious processes (eg, acne, herpes) in the&#xD;
             treatment area&#xD;
&#xD;
          -  Prior chin or jaw surgery, including cartilage grafts or implantation of any&#xD;
             biomaterials&#xD;
&#xD;
          -  Permanent filler, semi-permanent filler, or fat injected in the treatment area&#xD;
&#xD;
          -  Temporary filler, other than VOLUX, injected in the treatment area within 12 months&#xD;
             before enrollment&#xD;
&#xD;
          -  Females who self-report current pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hainan Boao Super Hospital /ID# 235968</name>
      <address>
        <city>Qionghai</city>
        <state>Hainan</state>
        <zip>571434</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

